Akari Therapeutics, Plc Current Liabilities
Akari Therapeutics, Plc (AKTX) had Current Liabilities of $13.94 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Liabilities, Current $13.94M.
- 2026-03-31: Liabilities, Current $13.41M.
- 2025-12-31: Liabilities, Current $12.35M.
- 2025-09-30: Liabilities, Current $15.57M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $13.94M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $13.41M 10-Q · filed 2026-05-19 | |
| 2025-12-31 | $12.35M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $15.57M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $17.14M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $20.91M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $19.91M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $9.43M 10-Q · filed 2024-11-19 | |
| 2024-06-30 | $24.03M 8-K · filed 2024-09-06 | $8.78M 10-Q · filed 2024-08-19 |
| 2024-03-31 | $6.33M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $4.58M 10-K · filed 2025-04-15 | |
| 2022-12-31 | $10.80M 8-K · filed 2024-09-06 | |
| 2018-12-31 | $4.92M 20-F · filed 2019-04-23 | |
| 2018-06-30 | $8.28M 6-K · filed 2018-09-27 | |
| 2017-12-31 | $11.85M 20-F · filed 2019-04-23 | |
| 2017-06-30 | $9.14M 6-K · filed 2017-08-10 | |
| 2016-12-31 | $11.71M 20-F · filed 2018-07-18 | |
| 2016-06-30 | $16.99M 6-K · filed 2017-04-14 | |
| 2016-03-31 | $16.55M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $21.12M 6-K · filed 2017-04-14 | |
| 2015-09-30 | $37.80M 10-Q · filed 2015-11-23 | |
| 2015-06-30 | $960.00K 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $910.00K 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $1.17M 10-K · filed 2016-03-23 | $1.36M 10-K · filed 2015-02-11 |
| 2013-12-31 | $1.23M 10-K · filed 2015-02-11 | |
| 2012-12-31 | $3.85M 20-F · filed 2014-03-24 | |
| 2011-12-31 | $2.24M 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |